tm logo
BRYLZ
REGISTERED

on 25 Oct 2024

Last Applicant/ Owned by

ELI LILLY AND COMPANY

Lilly Corporate CenterIndianapolis, IN 46285

US

Serial Number

2019330 filed on 25th Mar 2020

Registration Number

TMA1264981 registered on 25th Oct 2024

Registration expiry Date

25th Oct 2034

Correspondent Address

World Exchange Plaza100 Queen Street, Suite 1300Ottawa

ONTARIO

CA

K1P1J9

BRYLZ

Trademark usage description

pharmaceutical preparations namely pharmaceutical preparations for the treatment of alopecia, alzheimer's disease, anxiety disorders, atopic dermatiti Read More

Classification Information


Class [005]
Pharmaceutical preparations namely pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, anxiety disorders, atopic dermatitis, autoimmune diseases and disorders, axial spondyloarthritis, bone and skeletal diseases and disorders namely osteoporosis, osteoarthritis, fracture healing, bone frailty due to extended ventilator use, connective tissue diseases, bone diseases, spinal diseases, back pain, fractures, sprains, cartilage injuries, arthritis, bursitis, tendonitis, osteonecrosis and Paget's disease, cancer, cardiovascular diseases, central nervous system diseases and disorders namely, anxiety disorders, depression, bipolar depression, bipolar disorder, treatment resistant depression, schizophrenia and cognitive impairment associated with schizophrenia, cluster headaches, Crohn's disease, dementia, dermatological diseases and disorders namely psoriasis, skin cancer and eczema, diabetes, dyslipidemia, endocrine diseases and disorders, namely Type 2 Diabetes Mellitus and Type 1 Diabetes Mellitus, gastrointestinal diseases and disorders, headaches, heart failure, hypoglycemia, inflammation and inflammatory diseases and disorders namely inflammatory bowel diseases, inflammatory connective tissue diseases and rheumatoid arthritis, kidney diseases and disorders, liver diseases and disorders, lupus, mental diseases and disorders, namely mood disorders, schizophrenia, cognitive and bipolar disorders, epilepsy, and cerebral palsy, metabolic diseases and disorders namely metabolic syndrome, migraines, multiple sclerosis, muscle diseases and disorders namely myopathies, chronic fatigue syndrome, fibromyalgia and muscular dystrophy, neurodegenerative diseases and disorders namely Huntington's disease, Alzheimer's disease, and dementia, neurological disorders namely Alzheimer's disease, mild cognitive impairment, Parkinson's disease and multiple sclerosis, obesity, pain relief, Parkinson's disease, psoriasis, psoriatic arthritis, rheumatoid arthritis, Sjogren's syndrome, sleep disorders, spondyloarthropathy, systemic lupus erythematosus, ulcerative colitis; Diagnostic reagents for medical diagnostic use; radiopharmaceutical diagnostic preparations for use in the diagnosis of neurodegenerative diseases and of oncology and of pain


Classification kind code

12

Mark Details


Serial Number

2019330

Mark Type

Trademark

Legal History


Show more

Action TakenStatus
Submitted for opposition 190
on 25th Oct 2024
Registration Pending
Submitted for opposition 42
on 07th Aug 2024
Advertised
Submitted for opposition 26
on 11th Jul 2024
Approved
Submitted for opposition 27
on 11th Jul 2024
Approval Notice Sent
Submitted for opposition 22
on 03rd Jul 2024
Search Recorded
Submitted for opposition 287
on 11th May 2022
Pre-Assessment Letter Sent
Submitted for opposition 48
on 01st Feb 2022
Agent Changed
Submitted for opposition 30
on 25th Mar 2020
Filed
Submitted for opposition 1
on 25th Mar 2020
Created
Submitted for opposition 31
on 25th Mar 2020
Formalized